BioSpace News Archive

Replimune Group, Inc. a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that members from the Replimune management team will present and host investor meetings at the following two conferences.

Cerecor Inc., a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease Designation to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations.

Agreement provides use of extensive real world clinical data and clinical research samples across multiple high priority disease areas

7 Hills Pharma announced it had received broad patent protection from the U.S. Patent and Trademark Office on four patents covering the use of the company’s integrin activators with any therapeutic antibody, any checkpoint inhibitor for immuno-oncology, and any vaccine.

Electromedical Technologies, Inc. is pleased to announce that its Director of Technology, Mr. Petar Gajic, will establish a research and development office in Belgrade, Europe for the creation of new products and technologies.

Merck and Hanmi Pharmaceutical announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide, Hanmi’s investigational once-weekly glucagon-like peptide-1 /glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis.

Haemonetics Corporation announced that financial results for its first quarter fiscal 2021, which ended June 27, 2020, are available on its Investor Relations website.

Collaboration, Option and License Agreement Effective following HSR Clearance and $100 Million Up-Front Payment received by IDEAYA

Methodist Le Bonheur Healthcare is the first hospital system globally to participate in a landmark study using a first-of-its-kind EEG device.